New 18,500-Capacity Stadium Unveiled for Venezia, Design by Populous
24.4.2025 09:00:00 CEST | Business Wire | Press Release
Plans for a new city stadium – to be used for football, Serie A rugby and other events such as concerts – have been unveiled and presented to the Municipality of Venice.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250422302550/en/
Venice, 22 April 2025. New Stadium unveiled for Venezia, designed by Populous.
Maffeis Engineering and Populous, the world-leading sports architecture and design practice firm in the field of sports and entertainment, have been commissioned for the design and engineering work by the consortium of companies composed of Costruzioni Bordignon, Fincantieri Infrastrutture and Ranzato Impianti, which was awarded the contract for the project in March 2024.
The new Serie A stadium will have 18,500 seats. It will be part of a major sports masterplan built in Tessera in the new Bosco dello Sport, a multifunctional, 116-hectare hub in the northern part of the city, designed to integrate sport, social life, education and wellbeing.
The stadium’s design is inspired by the surrounding landscape, with curved lines that follow the wider masterplan, interacting with the nearby arena and sports center. The perimeter line also follows the overall organic layout: its clean structure is ideally placed within the Sports Forest like a pavilion in a garden.
The façade features a composition of vertical elements that rise upward in a regular pattern, creating a visible backdrop to the upper section of the seating bowl. This makes the stadium structure light and airy, allowing a view above the top of the stadium bowl.
The crescent-shaped podium gently embraces the stadium’s itself, becoming a strategic part of the structure, designed to house parking areas and other services.
The seating bowl develops in a semi-continuous section on the south, east, and north sides. Populous’ specialized designers have shaped it to offer optimal sightlines during matches. Its compact and monumental configuration ensures maximum fan experience while enhancing atmosphere.
VIP hospitality is based in the West Stand, offering premium and unique experiences. Dedicated spaces have been designed for the home fans, including a covered gallery surrounding the bowl 360 degrees, offering selected services and a breathtaking view of the surrounding landscape.
Overall, a diverse range of dining options and social spaces will make the experience even more enjoyable for all spectators. The stadium has been designed in accordance with the highest standards of inclusive design, allowing everyone to use and enjoy the venue.
The new Venice stadium will be able to transform to host Serie A rugby matches and live events such as concerts, making the facility even more vibrant and attractive for the local community.
Soil Engineering, Seingim, and Gae Engineering are also collaborating on the stadium project.
From Luigi Brugnaro, Mayor of the Municipality of Venice:
"I am truly proud and excited to present this project, a symbol of rebirth and an example of a city that wants to achieve. The time has come for us to have one of the most modern and cutting-edge stadiums in the world.
This will be an important project not only for our metropolitan area, but for the whole country. It will host football and rugby matches, as well as cultural events and concerts, and together with the new Arena, it will lead to the creation of jobs.
With the whole area of the Bosco dello Sport, Venice will finally have a new epicentre of sport, social life, inclusion and sustainability. I thank all those who, over the years, have worked to make this dream come true."
From Massimo Maffeis, CEO Maffeis Engineering:
“For us this stadium represents Venetians for Veneto. while we are used to working on international projects, there is an added emotion and motivation to work on a project that feels more ‘ours’ than many others. We are proud to be part of this project and of this team.”
From Silvia Prandelli, Senior Principal and General Manager of Populous Italia:
“The new Venice Stadium will give the city the sports infrastructure it deserves, with a unique design geared to enhancing the fan experience. Populous Italia is proud to contribute to the Bosco dello Sport project as well, a place where quality entertainment and sports activities at all levels will have a transformative and regenerative impact on the area. Together with its strategic location, this project will be a catalyst for the region, capable of attracting numerous national and international visitors.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20250422302550/en/
Contacts
Media Contacts:
Populous EMEA:
Charlie.brooks@populous.com
07881 268501
NIC Agency (Italia)
elisabetta.castellari@nicpr.it
+39 340 058 1336
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom